Evaluation of pain-related behavior, bone destruction and effectiveness of fentanyl, sufentanil, and morphine in a murine model of cancer pain

被引:32
作者
El Mouedden, M [1 ]
Meert, TF [1 ]
机构
[1] Johnson & Johnson Pharmaceut, Res & Dev, Div Janssen Pharmaceut, B-2340 Beerse, Belgium
关键词
bone cancer; cancer pain; fentanyl; morphine; sufentanil; opioid; marine model; osteolysis; CT-scan; trabecular bone structure;
D O I
10.1016/j.pbb.2005.07.016
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The present study was conducted to evaluate the pain development and bone destruction during bone cancer growth in a murine model of bone cancer pain and to evaluate the analgesic efficacy of fentanyl, sufentanil, and morphine in this model. C3H/HeNCrl mice were inoculated into the intramedullary space of the femur with osteolytic NCTC 2472 fibrosarcoma cells, and followed during a 3-week period to assess pain behaviors (spontaneous lifting and limb-use during forced ambulation on rotarod) and bone destruction (parameters indicative of bone lesions determined by mu CT-scans of the tumor-bearing bones) during bone cancer growth. The results showed that in this murine model of cancer-induced bone pain, behavioural manifestations of pain emerge in parallel with the progression of bone destruction. The Subcutaneous administration of fentanyl (0.025-0.64 mg/kg), sufentanil (0.005-0.04 mg/kg), and morphine (2.5-40 mg/kg) oil the test days 15 and 22 post-inoculation reduced pain-related behaviors in a dose dependent manner. A complete relief from pain-related behaviors was achieved with the following doses: >= 0. 16 mg/kg fentanyl, 0.02 mg/kg sufentanil, and 20 mg/kg morphine. In conclusion, the results showed a clear link between tumor growth-induced bone destruction and behavioral pain manifestations, the latter was effectively controlled by the opioids fentanyl, sufentanil, and morphine. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:109 / 119
页数:11
相关论文
共 39 条
[1]  
Berruti A, 1999, CLIN CHEM, V45, P1240
[2]   The management of cancer pain [J].
Cherny, NI .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (02) :70-116
[3]   Bone cancer pain [J].
Clohisy, DR ;
Mantyh, PW .
CANCER, 2003, 97 (03) :866-873
[4]   Osteoclasts are required for bone tumors to grow and destroy bone [J].
Clohisy, DR ;
Ramnaraine, ML .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1998, 16 (06) :660-666
[5]   Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts [J].
Clohisy, DR ;
Ogilvie, CM ;
Carpenter, RJ ;
Ramnaraine, MLR .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1996, 14 (01) :2-6
[6]  
Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO
[7]  
2-Z
[8]  
Coleman Robert E., 1998, Current Opinion in Oncology, V10, pS7
[9]   Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis [J].
Guise, TA ;
Yin, JJ ;
Taylor, SD ;
Kumagai, Y ;
Dallas, M ;
Boyce, BF ;
Yoneda, T ;
Mundy, GR .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (07) :1544-1549
[10]   Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord [J].
Honore, P ;
Luger, NM ;
Sabino, MAC ;
Schwei, MJ ;
Rogers, SD ;
Mach, DB ;
O'Keefe, PF ;
Ramnaraine, ML ;
Clohisy, DR ;
Mantyh, PW .
NATURE MEDICINE, 2000, 6 (05) :521-528